title: Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma.
authors.affiliation: Department of Ophthalmology, Flinders Medical Centre, Bedford Park, South Australia, Australia; Department of Ophthalmology, The University of Adelaide, Adelaide, South Australia, Australia.
authors.forename: Sudha
authors.initials: S
authors.lastname: Cugati
authors.forename: Jagjit Singh
authors.initials: JS
authors.lastname: Gilhotra
authors.forename: Stewart
authors.initials: S
authors.lastname: Lake
authors.forename: David L
authors.initials: DL
authors.lastname: Gordon
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000627:therapeutic use; D000283:Administration, Intravesical; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003131:Combined Modality Therapy; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D007167:Immunotherapy; D008297:Male; D014392:Tuberculosis, Ocular / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000276:Adjuvants, Immunologic; D000995:Antitubercular Agents; D001500:BCG Vaccine; D005938:Glucocorticoids